The annual Clinical Trials in Alzheimer’s Disease (CTAD) Congress brings together global experts to discuss developments in Alzheimer’s disease (AD) clinical research and showcase researchers’ work on AD trials. This article describes a recently initiated Phase II trial of a novel anti-tau monoclonal antibody, BMS-986446, the design for which was presented at the 17th CTAD Congress in Madrid, Spain, on 31st October 2024.
EMJ Neurology 13 [Supplement 3] . 2025
February 2025
Latest articles
All articles
7 Mins
13th
March
Does the Gut Microbiome Influence the Efficacy of Psychiatric Drugs?
Altered gut microbiome profiles correlate with anxiety and depression in humans, and work in animal models has identified specific…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
5 Mins
13th
March
Systemic Health Impact of Leaky Barriers in the Oral-Gut-Brain Axis
The human body is a holistic system, interconnected by the circulatory, nervous, lymphatic, endocrine, and immune systems that facilitate…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
5 Mins
13th
March
Infliximab-Induced Multifocal Motor Neuropathy
Multifocal motor neuropathy (MMN) is a rare immune-mediated disorder characterised by progressive, asymmetric muscle weakness…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
8 Mins
16th
January
Long-Term Patient Outcomes: The Role of Sustained Treatment Efficacy in Myasthenia Gravis
There have been great advances in the field of generalised myasthenia gravis (gMG) in recent years, but many patients remain dissatisfied…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.